Kolexia
Roche Henri Oncologie médicale
Roche Henri
Oncologie médicale
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
172 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Métastase lymphatique Tumeurs du sein triple-négatives Cancers du sein inflammatoires Récidive tumorale locale Carcinomes Carcinome canalaire du sein Syndrome mains-pieds

Collaborateurs

Voir plus
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Campone Mario
Campone Mario
Ico - Site Paul Papin, Angers, France
Goncalves Anthony
Goncalves Anthony
Centre Paoli-Calmettes, Marseille, France
Viens Patrice
Viens Patrice
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Amgen
2 collaboration(s)
Dernière en 2020
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
MAPAM-01: Therapeutic Nipple Areola Skin-sparing Mastectomy.
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   02 août 2023
CURSOC: Cost Utility of Radical Surgery in Ovarian Cancer
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   02 août 2023
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   11 avril 2022
Abstract P5-13-08: Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study
2021 San Antonio Breast Cancer Symposium   15 février 2022
EMBRACA: A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE
Essai Clinique (Pfizer)   20 décembre 2021
272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.
2021 ASCO Annual Meeting I   28 mai 2021
Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial.
2021 ASCO Annual Meeting I   28 mai 2021